Treatment Intensity And Duration In Patients Receiving First-Line Taxane Chemotherapy For Stage Iv Non-Small Cell Lung Cancer.

e19011 Background: In a phase III trial, weekly nab-paclitaxel (nab-P) plus carboplatin demonstrated a higher response rate than paclitaxel (P) every 3 weeks plus carboplatin, with less grade ≥ 3 neuropathy, neutropenia, arthralgia, and myalgia but more thrombocytopenia and anemia in patients with advanced NSCLC (Socinski et al. J Clin Oncol. 2012;30:2055-62). We hypothesized that these differences might lead to differences in cumulative dose received and regimen duration in clinical practice. Methods: Fully de-identified electronic medical records (EMRs) from October 1, 2012, to September 30, 2014, from a national EMR (OncoEMR; Altos Solutions) were analyzed. Patients receiving first-line therapy with either weekly P (P7), every 3 weeks P (P21), or weekly nab-P for stage IV NSCLC were identified. The majority of patients also received carboplatin. The total cumulative dose (mg/m2), treatment duration, and database persistence (a surrogate for overall survival) for the taxane regimens were determined. Reg...